ออฟไลน์ด้วยแอป Player FM !
Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia
Manage episode 454644127 series 1256601
Audio Journal of Oncology Podcast December, 2024:
Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia
Hua Zhang MD PhD (Chief Scientific Officer with SPH Biotherapeutics Limited, Shanghai and Hong Kong, China) tells the Audio Journal about the research findings he reported to the 2024 Annual Meeting of the American Society of Hematology in San Diego, USA.
“Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia”
Background:
Our previous study on co-administration of CD19- and CD22-CAR T cell therapy demonstrated durable remission in children with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL) (Wang et al. J Clin Oncol 2023; 41:1670-83). To further improve outcomes, we developed a bicistronic CD19/CD22 CAR (B019) aimed at enhancing event-free survival (EFS) and overall survival (OS) in the treatment of relapsed or refractory childhood B-ALL. The primary objectives were to assess EFS, OS, and safety of bicistronic CD19/CD22 CAR T cell in the treatment of patients with relapsed or refractory B-ALL with or without consolidative allogeneic stem cell transplant after CAR-T therapy.
51 ตอน
Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia
Manage episode 454644127 series 1256601
Audio Journal of Oncology Podcast December, 2024:
Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia
Hua Zhang MD PhD (Chief Scientific Officer with SPH Biotherapeutics Limited, Shanghai and Hong Kong, China) tells the Audio Journal about the research findings he reported to the 2024 Annual Meeting of the American Society of Hematology in San Diego, USA.
“Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia”
Background:
Our previous study on co-administration of CD19- and CD22-CAR T cell therapy demonstrated durable remission in children with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL) (Wang et al. J Clin Oncol 2023; 41:1670-83). To further improve outcomes, we developed a bicistronic CD19/CD22 CAR (B019) aimed at enhancing event-free survival (EFS) and overall survival (OS) in the treatment of relapsed or refractory childhood B-ALL. The primary objectives were to assess EFS, OS, and safety of bicistronic CD19/CD22 CAR T cell in the treatment of patients with relapsed or refractory B-ALL with or without consolidative allogeneic stem cell transplant after CAR-T therapy.
51 ตอน
כל הפרקים
×ขอต้อนรับสู่ Player FM!
Player FM กำลังหาเว็บ